Development of a mimotope-based vaccine against CD20 antigen

Protein Pept Lett. 2007;14(6):610-4. doi: 10.2174/092986607780989958.

Abstract

CD20, a B-cell-specific protein, is a primary target for immunotherapy of B-cell lymphomas. We used a mimotopes of CD20 to construct vaccines for B-cell-related disorders. The immunogenicity of the vaccines was tested in BALB/c mice. Results of this study suggest that the mimotope may be a useful tool for the construction of a functional vaccine to treat B cell-related disorders.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neoplasm / blood
  • Antibodies, Neoplasm / immunology
  • Antigens, CD20 / blood
  • Antigens, CD20 / chemistry
  • Antigens, CD20 / immunology*
  • Cancer Vaccines / immunology*
  • Cancer Vaccines / therapeutic use
  • Epitopes
  • Genetic Vectors
  • Hematologic Neoplasms / immunology
  • Hematologic Neoplasms / therapy
  • Immunotherapy
  • Lymphoma, B-Cell / immunology*
  • Lymphoma, B-Cell / therapy*
  • Mice
  • Mice, Inbred BALB C
  • Peptide Biosynthesis
  • Plasmids
  • Vaccines, Subunit / chemistry
  • Vaccines, Subunit / immunology
  • Vaccines, Subunit / therapeutic use

Substances

  • Antibodies, Neoplasm
  • Antigens, CD20
  • Cancer Vaccines
  • Epitopes
  • Vaccines, Subunit